Navigation Links
Endo Pharmaceuticals Reports Strong Fourth Quarter and Full-Year 2009 Financial Results: Provides 2010 Financial Guidance
Date:2/22/2010

d statements of operations: (1) To exclude amortization of commercial intangible assets related to marketed products. (2) To exclude separation costs of $10,459, impairment of long-lived assets of $1,482 and contract termination costs of $540. (3) To exclude upfront and milestone payments to partners of $8,910, separation costs of $825, impairment of long lived assets of $3,115 and contract termination costs of $4,551. (4) To exclude impairment of other intangibles. (5) To exclude purchased in-process research and development. (6) To exclude additional interest expense as a result of adopting ASC 470-20. (7) To exclude changes in fair value of financial instruments, net. (8) To reflect the tax effect of the pre-tax adjustments above at the applicable tax rates. For an explanation of Endo's reasons for using non-GAAP measures, see Endo's Current Report on Form 8-K filed today with the Securities and Exchange Commission. Reconciliation of Projected GAAP Diluted Earnings Per Share to Adjusted Diluted Earnings Per Share Guidance Year Ending Dec. 31, 2010 Projected GAAP diluted income per common share $2.40 To $2.45 Upfront and milestone payments to partners $0.12 $0.12 Amortization of commercial intangible assets $0.59 $0.59 Interest expense adjustment for ASC 470-20 and the amortization of the premium on debt acquired from Indevus $0.15 $0.15 Tax effect of pre-tax adjustments at the applicable tax rates and certain other expected cash tax savings as a result of the Indevus acquisition ($0.11) ($0.11) Diluted adjusted income pe
'/>"/>
SOURCE Endo Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... DUBLIN , Aug. 19, 2014 ... the "Pharmaceutical Contract Manufacturing - Global Strategic Business ... This report analyzes the worldwide markets for Pharmaceutical Contract ... Injectables (Injections, Vials, and IV solutions), Solid Dosage Forms ... (Syrups, Suspensions, Gels, Creams & Ointments). The ...
(Date:8/19/2014)... DUBLIN , Aug. 19, 2014 Research ... "Human Growth Hormone Drugs - Global Strategic Business Report" ... the worldwide markets for Human Growth Hormone Drugs in US$ ... and Others. The report provides separate comprehensive analytics ... Japan , Europe , ...
(Date:8/19/2014)... 2014  Boehringer Ingelheim today announced that the ... review the New Drug Application (NDA) for the ... via the Respimat ® inhaler for the ... airflow obstruction in patients with chronic obstructive pulmonary ... + olodaterol FDC will not be indicated to ...
Breaking Medicine Technology:Global Pharmaceutical Contract Manufacturing - Strategic Business Report 2014 2Global Human Growth Hormone Drugs - Strategic Business Report 2014 2Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 2Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 3Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 4Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 5Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 6Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 7Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 8
... Data from Serial Outpatient Infusion Study in Patients ... of Cardiology 56th Annual Scientific Session --, MOUNTAIN ... -- Scios Inc. announced today that an exploratory,920-patient, ... effect on the primary endpoint, a composite of ...
... March 26, 2007 /PRNewswire/ -- A large ... CYPHER(R) Sirolimus-eluting,Coronary Stent reported favorable safety and ... investigators at the of,Cardiology's 56th Annual Scientific ... a prospective, single-arm study designed,to evaluate the ...
Cached Medicine Technology:Scios Announces Results From Exploratory Nesiritide Study Providing,Important New Renal and Mortality Safety Data with a Neutral Effect,on the Primary Endpoint 2Scios Announces Results From Exploratory Nesiritide Study Providing,Important New Renal and Mortality Safety Data with a Neutral Effect,on the Primary Endpoint 3Scios Announces Results From Exploratory Nesiritide Study Providing,Important New Renal and Mortality Safety Data with a Neutral Effect,on the Primary Endpoint 4Scios Announces Results From Exploratory Nesiritide Study Providing,Important New Renal and Mortality Safety Data with a Neutral Effect,on the Primary Endpoint 5Scios Announces Results From Exploratory Nesiritide Study Providing,Important New Renal and Mortality Safety Data with a Neutral Effect,on the Primary Endpoint 6Scios Announces Results From Exploratory Nesiritide Study Providing,Important New Renal and Mortality Safety Data with a Neutral Effect,on the Primary Endpoint 7Two-Year Patient Registry Results Support Safety and Efficacy of,Cypher Sirolimus-Eluting Coronary Stent in 'Real World' Uses 2Two-Year Patient Registry Results Support Safety and Efficacy of,Cypher Sirolimus-Eluting Coronary Stent in 'Real World' Uses 3Two-Year Patient Registry Results Support Safety and Efficacy of,Cypher Sirolimus-Eluting Coronary Stent in 'Real World' Uses 4
(Date:8/20/2014)... In a recent article published by the ... (UCL) study showed that dental experts from around the ... was the most effective. Analysis of 66 different advice ... frequently recommended, but none were favored by a majority. ... experienced cosmetic dentist Dr. Patrick J. Broome, DMD, ...
(Date:8/20/2014)... NY (PRWEB) August 20, 2014 ... consecutive year on its 33rd annual Inc. 500|5000, ... companies. The list represents the most comprehensive look ... independent entrepreneurs. Companies such as Yelp, Pandora, Timberland, ... well-known names gained early exposure as members of ...
(Date:8/20/2014)... August 20, 2014 BuyCheapTicketsToEvents.com is ... wide selection of tickets to many events. Cheap NHL hockey ... begin in September. , Hockey fans are enthusiastic about their ... tickets for games. Now is the time to acquire 2014 ... in mere months. There will be a great deal of ...
(Date:8/20/2014)... 20, 2014 AttorneyOne.com, a recognized authority on ... from the FDA on Sodium Chloride IV . ... lot of Sodium Chloride IV 0.9%, USP 1000 mL, by ... presence of particulate matter. Sodium Chloride Injection, USP is used ... priming solution in hemodialysis procedures. , The reason ...
(Date:8/20/2014)... Kowa Optimed returns after a short hiatus ... new SL-17 portable slit lamp. , The SL-17 has ... controlled by an illuminated thumb wheel for easy adjustments ... available AAA rechargeable and dry cell batteries, which is ... designed specifically for the device. The new Sl-17 base ...
Breaking Medicine News(10 mins):Health News:Ending Confusion About the Best Way to Brush Teeth 2Health News:Ending Confusion About the Best Way to Brush Teeth 3Health News:Etransmedia Makes Exclusive List for the Eighth Consecutive Year in Inc. Magazine 2Health News:Etransmedia Makes Exclusive List for the Eighth Consecutive Year in Inc. Magazine 3Health News:2014 NHL Preseason Tickets Are Among Top Selling Seats at Trusted Provider BuyCheapTicketsToEvents.com 2Health News:Sodium Chloride IV 0.9% by Baxter Recalled: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Kowa Optimed (Booth MS13043) to Debut New Portable Slit Lamp at 2014 Vision Expo West in Las Vegas, Nevada 2
... the greater the chances , TUESDAY, May 4 (HealthDay ... her baby,s risk of developing psychiatric problems in childhood ... While there,s plenty of evidence that smoking during pregnancy ... such as asthma, ear infections and respiratory disease, this ...
... In an ... Program will be moving into a bigger office location on April 26. , ... Cincinnati, OH (PRWEB) May 4, 2010 -- The continued success ... facility away from their existing location on Pine Road in Kenwood. The office now occupies a ...
... ... LLP have again been named as Ohio Super Lawyers®. This honor, by the much respected ... accomplished medical malpractice attorneys. Congratulations! , ... Cleveland, OH (PRWEB) May 4, 2010 -- Spangenberg lawyers were again honored this ...
... ... prognostic testing system for individual patients announces new publications in major disease conditions validating ... US catch-up? , ... Michigan (Vocus) May 4, 2010 -- PrognostiCheck®, the noninvasive assessment of the presence, severity ...
... for providing better care to patients could end up ... belonging to racial and ethnic minorities, according to a ... a typical pay-for-performance program medical practices that serve vulnerable ... a result of existing gaps in the quality of ...
... experts add that painkiller,s other health benefits may outweigh possible ... British study finds that people who take aspirin every day ... devastating digestive illness. , But it,s still not very likely ... lead author said patients should keep in mind that aspirin ...
Cached Medicine News:Health News:Smoking While Pregnant May Raise Psychiatric Risks in Kids 2Health News:Smoking While Pregnant May Raise Psychiatric Risks in Kids 3Health News:UniqueU Medical Weight Loss Success Requires an Expansion and Move to a Larger Location 2Health News:Cleveland Attorneys Recognized as Ohio Super Lawyers on 2010 List 2Health News:Cleveland Attorneys Recognized as Ohio Super Lawyers on 2010 List 3Health News:"IPGDx, LLC Announces The Continued Validation Of Its Patented Technology For The Assessment Of Prognosis; PrognostiCheck" Getting the New Information to Patients and Do 2Health News:"IPGDx, LLC Announces The Continued Validation Of Its Patented Technology For The Assessment Of Prognosis; PrognostiCheck" Getting the New Information to Patients and Do 3Health News:Pay-for-performance programs may worsen medical disparities, study finds 2Health News:Pay-for-performance programs may worsen medical disparities, study finds 3Health News:Aspirin May Increase Risk of Crohn's Disease 2
... Laser System is a solid state Holmium: ... in all areas of the urinary tract, ... , ,A variety of reusable fibers provide ... clinical versatility and outcomes. Standard 115V electrical ...
... offers increased bone surface area contact between ... management of nonunions in long bones., ,Grid-Like ... of Contact on Host Bone , ,The ... cathode offers increased surface area and a ...
... proud to offer one of ... market at only 188 grams! ... a superior flow rate with ... mechanisms. The complementing electrodes provide ...
Flowmate makes portable uroflowmetry easy, accurate and dignified. Flowmate has automatic start and stop as well as simple and straightforward reporting from its own printer....
Medicine Products: